Beverly, Mass. — Inogen has appointed Andy Reding to the newly created position of chief operating officer, effective July 6.
Reding will oversee revenue and operational performance, coordinate priorities across the company and help translate Inogen’s strategy into measurable results.
Inogen is a medical technology company that develops respiratory products for use in home care.
“As we continue to diversify Inogen’s business through new product launches and geographic expansion, we are streamlining our leadership structure to enhance execution and accelerate delivery of our strategic priorities,” said Kevin Smith, Inogen’s Chief Executive Officer. “Andy’s deep experience building high-performing teams and scaling complex medical technology businesses will be invaluable as we continue to drive top-line growth, advance profitability and expand the innovation pipeline.”
Reding has more than 30 years of experience in medical technology, commercial operations, product development and healthcare reimbursement.
He most recently served as chief commercial officer of Viant Medical, where he spent more than six years leading teams supporting medical device design and manufacturing programs. Viant operates 25 facilities and serves hundreds of medical device companies.
“I am honored to join Inogen at such an important time in the company’s evolution,” said Andy Reding. “Inogen has a strong foundation, a compelling mission, and significant opportunities to expand its impact for patients and providers globally. I look forward to working with Kevin and the broader team to transform Inogen into a global respiratory care leader.”
Reding previously served as vice president and general manager of Hillrom Respiratory Health, where he oversaw sales, marketing, customer service, research and development, reimbursement and third-party billing.
During his tenure, the business expanded its sales force, developed new products and navigated regulatory and reimbursement requirements from the U.S. Food and Drug Administration and the Centers for Medicare and Medicaid Services.
Reding holds a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.
As part of his employment agreement, Reding will receive restricted stock units covering 130,000 shares of Inogen common stock. One-third of the shares will vest annually over three years, subject to his continued employment.
The equity award was approved under Nasdaq Listing Rule 5635(c)(4).
